Interested in learning more about what our CEO Nicholas Siciliano thinks about the future of CAR-T? Check out the latest edition of pharmaphorum's Deep Dive to read his thoughts on what's ahead for the CAR-T field and how Vittoria is helping to solve key challenges in the "second inning" of the technology. https://lnkd.in/eJEKup3V
Vittoria Biotherapeutics, Inc.
Biotechnology Research
Philadelphia, Pennsylvania 1,328 followers
Vittoria Biotherapeutics is committed to unlocking the promise of cell therapies to address unmet clinical needs.
About us
Vittoria Biotherapeutics is committed to unlocking the promise of cell therapies while addressing their inherent challenges by strengthening efficacy, improving safety, and broadening therapeutic applicability for patients with difficult-to-treat diseases. An Important Note About Privacy: Vittoria Biotherapeutics is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth, or bank account details via email, job recruiting, or social media platforms. We do not hire virtually or solicit/interview candidates on Indeed, Telegram, Wire, Google Hangouts or similar public platforms. Any questions about career opportunities can be directed to info@vittoriabio.com.
- Website
-
http://www.vittoriabio.com
External link for Vittoria Biotherapeutics, Inc.
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Philadelphia, Pennsylvania
- Type
- Privately Held
- Founded
- 2021
- Specialties
- CART immunotherapy, Lymphoma, Leukemia, Gene editing, Cell engineering, Cancer, chimeric antigen receptor, CD5, Myeloma, T cells, Hematology, CRISPR, CRISPR-Cas9, biotherapeutics, Patient, Physician, SHP-1, CD2, CD7, CD30, and DIAGNOSIS
Locations
-
Primary
Get directions
3675 Market St
Suite 200
Philadelphia, Pennsylvania 19104, US
Employees at Vittoria Biotherapeutics, Inc.
Updates
-
Thank you Cell & Gene for having us on! If you want to hear more about our CEO Nicholas Siciliano's POV on the current state of cell therapy manufacturing and the next evolution of #automation, check out the webinar link below.
If you missed Tuesday's Cell & Gene Live, Inside Next-Gen Platforms for Cell Therapy Manufacturing, it's available on demand. Vittoria Biotherapeutics, Inc.' co-founder and CEO,Nicholas Siciliano, Ph.D. and Will Junker, former Head of Quality Engineering and Head of Vector Quality at Kite, joined me for a detailed discussion on the platforms shaping #automation and #robotics, closed system manufacturing, advanced #analytics, #scalability, and more. #cellandgenetherapy #cgt #celltherapymanufacturing #cellandgenelive
Inside Next-Gen Platforms For Cell Therapy Manufacturing
cellandgene.com
-
We are gearing up for the American Society of Clinical Oncology (ASCO) annual meeting! Our executive team is excited to immerse themselves in the latest breakthroughs and advancements in cancer research. See you there! #ASCO2024 #CancerResearch #BiotechInnovation
-
In the most recent Spring Edition of Drug Discovery World, our CEO, Nicholas Siciliano, shares insights on the curative potential of CAR-T therapeutics and how Vittoria is helping shape the future of immunotherapy. To check out the full piece, read here: https://shorturl.at/bcrtN
Drug Discovery World - Drug Discovery World (DDW)
https://www.ddw-online.com
-
We're thrilled to welcome Keith Westby as our inaugural Chief Operating Officer! With his wealth of experience and successful track record in the drug development space, we're poised to reach new heights in our mission to revolutionize CAR-T therapeutics. https://lnkd.in/eNNRvU6R
-
-
Curious about what strategies biotech companies are implementing to enable accelerated product development and commercialization while still maintaining quality? Our co-founder and CEO Nicholas Siciliano weighed in with his insights for a recent Pharma's Almanac Roundtable article! Check out what techniques Vittoria is harnessing to advance their science: https://bit.ly/49QFtFN.
-
-
We’re thrilled to formally welcome Dr. Mazanet to the Vittoria team! As demonstrated by her 20+ years of success across all drug development facets, she will make a tremendous contribution to our mission of delivering next generation cell therapies to patients with difficult-to-treat diseases. https://lnkd.in/eCjkGm_y
-
-
What does 2024 have in store for biopharma? Our co-founder and CEO Nicholas Siciliano weighed in with his predictions for the next evolution of therapeutic area advancements in the latest #ScripsAsks series. Hear what he has to say about where the industry is headed in addressing the limitations of current cell therapies: https://shorturl.at/mopry
-
-
We’re thrilled to announce we received FDA clearance on our IND application for our VIPER-101 candidate, as a potential treatment for T-cell Lymphoma patients. Today’s news underscores a significant achievement, as Vittoria transitions to a clinical stage company and moves one step closer to bringing life changing solutions to patients. To learn more, read here: https://shorturl.at/qyAJV
-
-
Today we announced multiple abstract presentations at the 65th Annual American Society of Hematology conference in San Diego! Stop by our presentations to learn more about our Senza5 platform and how we’re advancing novel therapeutic solutions for #oncology and #immunology patients. See details here: https://shorturl.at/oGW26
-